Drugs / haNK for infusion
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03387098 | Dec 2017 → Sep 2018 | malignant pancreatic neoplasm | ImmunityBio, Inc. | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | haNK for infusion | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03387098 ↗ |
| Modality | Cell therapy | “Innate High-affinity Natural Killer (haNK) Cell Therapy” NCT03387098 ↗ |